Abstract

FORMULATION, DEVELOPMENTAND EVALUATION OF EXTENDED-RELEASE TABLET OF CARVEDILOL PHOSPHATE

Swati S. Rawat* and Abhishek S. Shahane

Abstract

The oral route is the most popular route due to ease of administration and to the fact that gastrointestinal physiology offers more flexibility. The matrix system is one of the intricate approaches for the preparation of the sustained release dosage forms and formulation of matrix tablet has gained immense popularity now a day because it has the advantage of simple processing and low cost of fabrication. Formulated oral sustained release matrix tablets of Carvedilol Phosphate in order to improve efficacy, reduce the frequency of administration, and better patient compliance. Matrix tablet of Carvedilol Phosphate, prepared using Sodium carboxymethyl cellulose and HPMC K4M can successfully be employed in oral controlled release drug delivery system, as it is likely to increase its GI residence time, and eventually, improve the extent of bioavailability. However, appropriate balancing between various levels of the two polymers is imperative to acquire proper controlled release. The physicochemical compatibility of the drug with polymers was established through FTIR spectroscopy. All blended formulations were evaluated for bulk density, tapped density, Carr’s index, angle of repose and the Hausner’s ratio. All these results indicated that, the powder blend showed good flow properties. All tablet formulation has their weight within 498 to 501 mg and were uniform in diameter. The formulation batch F1 and batch F9, all trials have the sufficient hardness and friability i.e., with in the limit. In dissolution studies formulation F7 given best drug release up to the 24 hrs compared to other formulation and it follows zero order kinetics. Accelerated stability studies results were found within limits.. Extended release tablet of Carvedilol Phosphate can be successfully employed to treat hypertension and congestive heart failure condition.

Keywords: Zero order kinetics, Higuchi model, Korseymey-peppas model, Carvedilol Phosphate, Sodium CMC and HPMC K4M.